Published: Tue, March 13, 2018
IT&Software | By Alfonso Woods

Ziopharm Oncology In (ZIOP): Stock Overview


Ziopharm Oncology In (NASDAQ:ZIOP) has a Return on Assets (ROA) of -66.1.

Technical analysis of ZIOPHARM Oncology, Inc. The stock's quarterly performance specifies a shift of 2.75%, and its last twelve month performance is stands at -29.56% while moved -30.54% for the past six months. About 2.57M shares traded.

Among 4 analysts covering Ziopharm Oncology (NASDAQ:ZIOP), 1 have Buy rating, 0 Sell and 3 Hold. It has underperformed by 16.70% the S&P500. The stock has a market capitalization of $649.02, a price-to-earnings ratio of -8.04 and a beta of 1.42. The Q.i. Value is a helpful tool in determining if a company is undervalued or not.

The stock decreased 0.55% or $0.03 during the last trading session, reaching $5.47. About 27,733 shares traded. It is down 0.00% since March 7, 2017 and is. It has outperformed by 26.62% the S&P500.

Ziopharm Oncology In (NASDAQ:ZIOP) has grabbed attention from the analysts, when it saw a value increase of 5.34% or 0.22 points in the last trading session to close at $4.34. Raymond James initiated the stock with "Market Perform" rating in Thursday, June 2 report. The mean rating score for this stock is at 2.50. As per Thursday, December 14, the company rating was maintained by H.C. Wainwright. The Gross Margin Score of ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) rating on Monday, January 25. The share price has moved away from its 20 days moving average at the rate of 53.23% and its 50 days moving average returned 37.35%. (NASDAQ:ZIOP) rating on Monday, January 25. The firm has "Neutral" rating by Mizuho given on Wednesday, May 11.

Several equities analysts recently issued reports on ZIOP shares.

ZIOPHARM Oncology, Inc.is a biopharmaceutical company engaged in the development and commercialization of a diverse, risk-sensitive portfolio of in-licensed cancer drugs to address unmet medical needs. In order for us to accurately measure profitability and return, we will be using the EBITDA margin and Return on Investment (ROI), which balances the difference in capital structure. Similarly, the Earnings Yield Five Year Average is the five year average operating income or EBIT divided by the current enterprise value. The Company's synthetic immuno-oncology platform employs an inducible gene-delivery system that enables controlled in vivo expression of genes that produce therapeutic proteins to treat cancer. This ratio is calculated by dividing the current share price by the book value per share. Vanguard Index Fds (VB) was raised too. The Germany-based Flossbach Von Storch Ag has invested 4.87% in Monsanto Company (NYSE:MON). Its up 0.17, from 1.1 in 2017Q2. It improved, as 7 investors sold Regis Corporation shares while 43 reduced holdings. 92 funds opened positions while 249 raised stakes. The volume of 1.21 Million shares climbed down over an trading activity of 1.91 Million shares. 59 are held by Hanson Mcclain Incorporated. 0 analysts call it Underweight, while 2 think it is Overweight. $966,720 worth of Monsanto Company (NYSE:MON) shares were sold by MIZELL STEVEN. Sigma Planning Corporation has 3,131 shares. Systematic Mgmt Limited Partnership invested 0.33% of its portfolio in Cummins Inc. The FCF Growth of EP Energy Corporation (NYSE:EPE) is -0.532886. (NYSE:CMI) for 1,281 shares. 1 is equivalent to a buy rating, 3 a hold rating, and 5 a sell rating. Therefore 34% are positive. The firm earned "Underperform" rating on Friday, December 4 by Wells Fargo.

Anthem, Inc. (NYSE:ANTM) closed at $228.79 a share in the latest session and the stock value rose nearly 1.68% since the beginning of this year. (NASDAQ:ZIOP) on Thursday, December 14 with "Buy" rating. Morgan Stanley reinitiated the stock with "Overweight" rating in Thursday, August 27 report. The company was maintained on Wednesday, October 28 by Barclays Capital. (NYSE:ANTM) is noted at 5.11.

Analysts await Cummins Inc. BlackRock Inc. now owns 8,499,209 shares of the biotechnology company's stock valued at $35,187,000 after acquiring an additional 280,003 shares in the last quarter. MON's profit would be $1.49B giving it 9.10 P/E if the $3.39 EPS is correct. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, hitting the Thomson Reuters' consensus estimate of ($0.13).

Latest analyst recommendations could offer little help to investors.

Like this: